Literature DB >> 19430910

A multi-tiered analytical approach for the analysis and quantitation of high-molecular-weight aggregates in a recombinant therapeutic glycoprotein.

Heather Hughes1, Charles Morgan, Elizabeth Brunyak, Kristen Barranco, Emily Cohen, Tim Edmunds, Karen Lee.   

Abstract

In this study, we have investigated sedimentation velocity ultracentrifugation (AUC-SV), size exclusion chromatography (SEC), and circular dichroism (CD) methods for the detection and quantitation of protein aggregates using recombinant acid alpha-glucosidase (rhGAA) as a model. The results of this study showed that the formation and molecular weight distribution of rhGAA aggregated species were dependent upon the formulation conditions as well as the storage or stress conditions used to induce aggregation. The utility of CD as a probe for non-native, aggregated species was affirmed, as this method was sensitive to rhGAA aggregation levels of < or = 4%. An extensive evaluation of AUC-SV variability was performed using nine levels of spiked rhGAA aggregate that were analyzed on six occasions. Based on our data, the precision of the AUC-SV results increased with increasing levels of aggregate, with a mean RSD of 37.2%. The limit of quantitation (LOQ) for the AUC-SV method, which was based on a Precision criterion of RSD < 20%, was determined to be > or = 3% aggregated rhGAA. The Precision and LOQ of the SEC method, determined using the same rhGAA sample set, was found to be 3.8% and > or = 0.2%, respectively. In general, there was good agreement between the levels of aggregated rhGAA determined using the AUC-SV and SEC methods, with a slight positive bias noted for the AUC-SV results. These studies emphasize the value of applying multiple, well-characterized analytical tools in the evaluation of therapeutic protein aggregation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19430910      PMCID: PMC2691468          DOI: 10.1208/s12248-009-9108-1

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  18 in total

Review 1.  Role of analytical ultracentrifugation in assessing the aggregation of protein biopharmaceuticals.

Authors:  Steven A Berkowitz
Journal:  AAPS J       Date:  2006-09-22       Impact factor: 4.009

2.  Quantitation of aggregate levels in a recombinant humanized monoclonal antibody formulation by size-exclusion chromatography, asymmetrical flow field flow fractionation, and sedimentation velocity.

Authors:  John P Gabrielson; Mark L Brader; Allen H Pekar; Kathrin B Mathis; Gerhard Winter; John F Carpenter; Theodore W Randolph
Journal:  J Pharm Sci       Date:  2007-02       Impact factor: 3.534

3.  Quantitation of aggregates in therapeutic proteins using sedimentation velocity analytical ultracentrifugation: practical considerations that affect precision and accuracy.

Authors:  Allen Pekar; Muppalla Sukumar
Journal:  Anal Biochem       Date:  2007-04-27       Impact factor: 3.365

Review 4.  Immunogenicity of protein therapeutics.

Authors:  Anne S De Groot; David W Scott
Journal:  Trends Immunol       Date:  2007-10-25       Impact factor: 16.687

5.  Effects of solution conditions, processing parameters, and container materials on aggregation of a monoclonal antibody during freeze-thawing.

Authors:  Lisa A Kueltzo; Wei Wang; Theodore W Randolph; John F Carpenter
Journal:  J Pharm Sci       Date:  2008-05       Impact factor: 3.534

6.  Biochemical and pharmacological characterization of different recombinant acid alpha-glucosidase preparations evaluated for the treatment of Pompe disease.

Authors:  A J McVie-Wylie; K L Lee; H Qiu; X Jin; H Do; R Gotschall; B L Thurberg; C Rogers; N Raben; M O'Callaghan; W Canfield; L Andrews; J M McPherson; R J Mattaliano
Journal:  Mol Genet Metab       Date:  2008-06-05       Impact factor: 4.797

7.  Common excipients impair detection of protein aggregates during sedimentation velocity analytical ultracentrifugation.

Authors:  John P Gabrielson; Kelly K Arthur; Brent S Kendrick; Theodore W Randolph; Michael R Stoner
Journal:  J Pharm Sci       Date:  2009-01       Impact factor: 3.534

8.  A role for protein misfolding in immunogenicity of biopharmaceuticals.

Authors:  Coen Maas; Suzanne Hermeling; Barend Bouma; Wim Jiskoot; Martijn F B G Gebbink
Journal:  J Biol Chem       Date:  2006-11-29       Impact factor: 5.157

9.  A bayesian approach for quantifying trace amounts of antibody aggregates by sedimentation velocity analytical ultracentrifugation.

Authors:  Patrick H Brown; Andrea Balbo; Peter Schuck
Journal:  AAPS J       Date:  2008-09-24       Impact factor: 4.009

10.  Studying the formation of aggregates in recombinant human granulocyte-colony stimulating factor (rHuG-CSF), lenograstim, using size-exclusion chromatography and SDS-PAGE.

Authors:  Jasmina Tonic Ribarska; Suzana Trajkovic Jolevska; Ana Poceva Panovska; Aneta Dimitrovska
Journal:  Acta Pharm       Date:  2008-06       Impact factor: 2.230

View more
  3 in total

1.  A platform for characterizing therapeutic monoclonal antibody breakdown products by 2D chromatography and top-down mass spectrometry.

Authors:  Matthew T Mazur; Richard S Seipert; David Mahon; Qinwei Zhou; Tun Liu
Journal:  AAPS J       Date:  2012-05-12       Impact factor: 4.009

2.  Detection of high-molecular-weight amyloid serum protein complexes using biological on-line tracer sedimentation.

Authors:  Jonathan S Kingsbury; Thomas M Laue; Susan F Chase; Lawreen H Connors
Journal:  Anal Biochem       Date:  2012-03-27       Impact factor: 3.365

3.  Size-Exclusion Chromatography for the Analysis of Protein Biotherapeutics and their Aggregates.

Authors:  Paula Hong; Stephan Koza; Edouard S P Bouvier
Journal:  J Liq Chromatogr Relat Technol       Date:  2012-11-30       Impact factor: 1.467

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.